Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 39, Issue 4, 2016, Pages 363-367

  Stuckey, Ashley ^a,b   Febbraro, Terri ^a   Laprise, Jessica ^a   Wilbur, Jennifer S ^a   Lopes, Vrishali ^a   Robison, Katina ^a  

^a BROWN UNIVERSITY   (United States)

^b Program in Women's Oncology   (United States)

Author keywords

BRCA mutation; breast cancer; genetic referral

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PATIENT REFERRAL; PRACTICE GUIDELINE; PROPHYLACTIC SURGICAL PROCEDURE; PROTOCOL COMPLIANCE; TUMOR SUPPRESSOR GENE; AGE; BREAST NEOPLASMS; CLINICAL PRACTICE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROPHYLACTIC MASTECTOMY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ADULT; AGE FACTORS; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GUIDELINE ADHERENCE; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROPHYLACTIC MASTECTOMY; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES;

EID: 84897360608     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000073     Document Type: Article

References (31)

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.
2. NCCN guidelines version 4. 2013. Available at: http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf. Accessed February 2, 2014.
3. Myriad Genetics. Available at: https://s3.amazonaws.com/myriadlibrary/brac/brca prevalence-tables.pdf. Accessed February 9, 2014.
4. Brown KL, Hutchison R, Zinberg RE, et al. Referral and experience with genetic testing among women with early onset breast cancer. Genet Test. 2005;9:301-305.
5. Schwartz M, Lerman C, Brogan B, et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14:1003-1007.
6. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887-5892.
7. Weitzel JN, McCaffrey SM, Nedelcu R, et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg. 2003;138:1323-1328.
8. Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121:389-398.
9. Schwartz MD, Lerman C, Brogan B, et al. The impact of BRCA1/2 counseling and testing in newly diagnosed breast cancer patients. J Clin Oncol. 2004;22:1823-1829.
10. Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13: 349-355.
11. Kaplan C, Haas J, Perez-Stable E, et al. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med. 2005;41:7-15.
12. Trivers K, Baldwin L, Miller J, et al. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians. Cancer. 2011;117:5334-5343.
13. O'Neill SM, Peters JA, Vogel VG, et al. Referral to cancer genetic counseling: are there stages of readiness? Am J Med Genet Part C Semin Med Genet. 2006;142C:221-231.
14. van Riel E, Warlam-Rodenhuis C, Verhoef S, et al. BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing. Eur J Cancer Care. 2010;19:369-376.
15. Schlich-Bakker KJ, Wárlám-Rodenhuis CC, van Echtelt J, et al. Short term psychological distress in patients actively approached for genetic counseling after diagnosis of breast cancer. Eur J Cancer Care. 2006;42:2722-2728.
16. Schlich-Bakker KJ, Ausems M, Schipper M, et al. BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Res Treat. 2007;109:507-514.
17. Schlich-Bakker KJ, ten Kroode H, Warlam-Rodenhuis CC, et al. Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer. Genet Med. 2007;9:766-777.
18. Frojd C, Von Essen L. Is doctors' ability to identify cancer patients' worry and wish for information related to doctors' selfefficacy with regard to communicating about difficult matters? Eur J Cancer Care. 2006;15:371-378.
19. Butow PN, Dunn SM, Tattersall MH, et al. Computer-based interaction analysis of the cancer consultation. Br J Cancer. 1995;71:1115-1121.
20. Pieterse AH, Ausems MG, Van Dulmen AM, et al. Initial cancer genetic counseling consultation: change in counselees' cognitions and anxiety, and association with addressing their needs and preferences. Am J Med Genet. 2005;137:27-35.
21. Geer KP, Ropka ME, Cohn WF, et al. Factors influencing patients' decisions to decline cancer genetic counseling services. J Genet Couns. 2001;10:25-40.
22. Lowstuter K, Sand S, Blazer K, et al. Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. Genet Med. 2008;10:691-698.
23. Azyolinsky A. Supreme court ruling broadens BRCA testing options. J Natl Cancer Inst. 2013;105:1671-1672.
24. Powell C, Littell R, Hoodfar E, et al. Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling? Int J Gynecol Cancer. 2013;23:431-436.
25. Vogel T, Stoops K, Bennett R, et al. A self-administered family history questionnaire improves identification of women who warrant referral to genetic counseling for hereditary cancer risk. Gynecol Oncol. 2012;125:693-698.
26. Watson E, Clements A, Yudkin P, et al. Evaluation of the impact of two educational interventions on GP management of familial breast/ovarian cancer cases: a cluster randomised controlled trial. Br J Gen Pract. 2001;51:817-821.
27. Breheny N, Geelhoed E, Goldblatt J, et al. Economic evaluation of the familial cancer services program in WA: predictive genetic testing for FAP and HNPCC. Commun Genet. 2006;9:98-106.
28. Breheny N, Geelhoed E, Goldblatt J, et al. Cost-effectiveness of predictive genetic tests for familial breast and ovarian cancer. Genom Soc Policy. 2005;1:67-79.
29. US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;143: 355-361.
30. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055-1062.
31. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80-87.